CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01077128
NCT01077128N/ACompleted

[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study

AbbVie (prior sponsor, Abbott)·observational·Posted Feb 26, 2010·Updated Feb 21, 2014

In Brief

An observational study for Psoriasis. Completed, enrolled 500 participants across 61 sites.

Detailed Summary

Primary objective * To evaluate the quality of life of Adalimumab treated patients over a period of 12 months Secondary objectives * To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe chronic plaque psoriasis as prescribed by the dermatologists in day-to-day clinical practice and in accordance with the terms of the European marketing authorization. * To evaluate changes in patients quality of life according to treatment response over a 12-month period * To observe and assess the long term use and safety of Adalimumab as prescribed by the dermatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2010
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.3 years ago